It is tempting to speculate that this putative disadvantage from early exposure to chemotherapy might be even more important for ALK+ lung cancers compared to other NSCLC, because of the particularly low baseline TMB of ALK+ disease [19]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.